The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
|Articles|April 2, 2015
Certara Launches Cardiac Safety Simulator V2.0
Certara®, a global biosimulation technology-enabled consultancy, announced version 2.0 of its Cardiac Safety Simulator (CSS), which has become a standalone product for the first time. CSS is an alternative to Thorough QT/QTc (TQT) studies.
Advertisement
Certara®, a global biosimulation technology-enabled consultancy, announced version 2.0 of its Cardiac Safety Simulator (CSS), which has become a standalone product for the first time. CSS is an alternative to Thorough QT/QTc (TQT) studies. CSS uses drug-triggered cardiac ion-current disruption data, together with predicted in-vivo exposure information to evaluate the factors influencing potential cardiac risk.
CSS v2.0 offers new features including the following:
- Enhanced QSAR models for predicting drug-triggered IKr, IKs, INa and ICaL current inhibition based on automatically-calculated phys-chem data (when in-vitro data are not available)
- Predicts population variability and drug-triggered physiology modifications
- Permits assessment of the potential impact of disease and genotypes; allows for genotype-related ionic current modification at the multiple channels level
- Contains an additional human left ventricular muscle cell model
- Evaluates up to seven chemical species (drugs, metabolites and other substances) simultaneously that are interacting at the ion channel(s) level
- Provides a new flexible, Excel-based tool to enhancevisualization and analysis of simulation results
Advertisement
Related to this article
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Where AI Leads in Trial Design—and Where Humans Still Need To
3
Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?
4
The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility
5